Blog

A New Treatment Option for Advanced EGFR-Mutant NSCLC – IASLC

IASLC/X

Jul 20, 2025, 19:20

A New Treatment Option for Advanced EGFR-Mutant NSCLC – IASLC

International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn:

“A new treatment option has entered the landscape for patients with advanced EGFR-mutant NSCLC.

In the latest Lung Cancer Considered, Dr. Narjust Florez sits down with Dr. Jacob Sands to review the FDA approval of datopotamab deruxtecan for patients who have progressed on both EGFR-targeted therapy and platinum-based chemotherapy.

The conversation highlights trial data, patient selection, and what this new approval means for clinical practice.

Listen now.”

More posts featuring IASLC.

cancer datopotamab deruxtecan IASLC International Association for the Study of Lung Cancer Jacob Sands Lung cancer Lung Cancer Considered Narjust Florez NSCLC OncoDaily Oncology

ASCO 2026 Presidential Theme: Dr. Eric Small’s Vision to Translate Science Into Global Cancer Impact

MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress

Tabelecleucel (Ebvallo) FDA Update: Approval Delayed Despite Positive Phase 3 Data

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

"God Invented This" - Pat Soon-Shiong on Cancer Discovery